- ACA Implementation & State Health Reform
- Coverage and Access
- Federal/State Issues
- Medicaid and CHIP
- Population and Public Health
- Providers and Services
- Acute Care
- Assisted Living
- Behavioral Health
- Case Management
- Child Development Services
- Chronic Care Management
- Community Health Centers
- Developmental Screening
- Early Childhood Services
- Emergency Care
- EPSDT
- Family Planning
- Federally Qualified Health Centers
- Home & Community Based Services
- Hospitals
- Long Term Services & Supports
- Medical Homes & Health Homes
- Mental Health
- Nursing Homes
- Oral Health
- Preventive Care
- Primary Care
- Safety Net Providers
- Quality, Cost, and Health System Performance
- ACOs
- Adverse Event Reporting
- Care Transitions
- Comparative Effectiveness
- Cost Sharing
- Delivery System Reform
- Fraud and Abuse
- Health Care Workforce
- Health Information Technology
- Managed Care
- Medical Homes & Health Homes
- Medical Malpractice
- Patient Safety
- Payment Reform
- Performance Measurement
- Provider Payment Policy
- Quality Oversight
- Specific Populations
- Adolescents
- Childless Adults
- Children
- Children with Special Health Care Needs
- Dual Eligibles
- Elders
- Families
- Low Income People
- Parents
- People with Chronic Conditions
- People with Developmental Disabilities
- Transitional Youth
- Vulnerable Populations
- Young Adults
- Youth
- Youth in Foster Care System
- Youth in Juvenile Justice System
-
Understanding Key Features of the Drug Effectiveness Review Project (DERP) and Lessons for State Policy Makers
This brief summarizes the key features of the Drug Effectiveness Review Project (DERP). The DERP is a collaborative partnership between states and other government and non-profit entities that conducts systematic evidence-based reviews of pharmaceuticals. It is the largest effort to apply current best practices and evidence-based analysis to pharmacy management issues.March 2006 -
State Experience in Creating Effective P&T Committees
This brief summarizes state experience in creating and managing Pharmaceutical and Therapeutics (P&T) committees. The brief points out that states face critical issues in designing and implementing their efforts that range from the make-up of their P&T committees, to the way in which prior approval requests are submitted.March 2006 -
State Design and Use of Prior Authorization Processes
This brief summarizes six state’s experiences in implementing and operating prior authorization (PA) processes that support a preferred drug list (PDL). The PA process can be divided into three major components: Submission, Review, and Appeal. This brief examines state policy choices and experience in each of these areas. It also examines two common means these states established for bypassing the PA process – emergency supplies and the Dispense as Written (DAW) provision.March 2006
